Article Per Year (5 Year)
p-Index From 2020 - 2025
0.61
P-Index
This Author published in this journals
All Journal Acta Pharmaciae Indonesia : Acta Pharm Indo
Masita Wulandari Suryoputri
Department of Pharmacy, Faculty of Health Sciences, Universitas Jenderal Soedirman. Purwokerto (Indonesia)
Medicine & Pharmacology

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Faktor-Faktor Yang Berhubungan Dengan Luaran Klinis Asam Valproat Pada Epilepsi Pediatri Dewi Latifatul Ilma; Nialiana Endah Endriastuti; Masita Wulandari Suryoputri
Acta Pharmaciae Indonesia : Acta Pharm Indo Vol 9 No 1 (2021): Acta Pharmaciae Indonesia : Acta Pharm Indo
Publisher : Pharmacy Department, Faculty of Health Sciences, Jenderal Soedirman University, Purwokerto, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20884/1.api.2021.9.1.4060

Abstract

Epilepsi merupakan penyakit kronis dengan prevalensi tinggi pada pediatrik. Salah satu obat anti epilepsi yang banyak diresepkan pada pediatrik adalah asam valproat. Luaran klinis utama pengobatan anti epilepsi adalah tercapainya periode bebas kejang. Tercapainya luaran klinis epilepsi sulit diprediksi karena dipengaruhi oleh banyak faktor. Penelitian ini bertujuan untuk menganalisis faktor-faktor yang berhubungan dengan luaran klinis pasien epilepsi pediatrik yang menggunakan asam valproat. Pengambilan data dilakukan melalui wawancara kepada orangtua/wali pasien. Epilepsi dikatakan terkontrol jika tercapai periode bebas kejang ≥6 bulan selama menggunakan asam valproat. Analisis data dilakukan dengan uji chi square atau uji Fisher, dilanjutkan dengan uji regresi logistik binomial. Pasien pada penelitian ini berjumlah 39 pasien. Sebagian besar pasien pediatri (64.1%) yang menggunakan terapi asam valproat memiliki epilepsi yang terkontrol, dengan 20 pasien (51.3%) menggunakan monoterapi asam valproat. Faktor yang berhubungan dengan luaran klinis pasien adalah jumlah obat antiepilepsi yang digunakan (p-value <0.05).
Drug utilization of N-Acetylcysteine in COVID-19 inpatients at Santa Elisabeth Hospital, Purwokerto Heny Ekowati; Faradina Qorina Nadzif; Masita Wulandari Suryoputri
Acta Pharmaciae Indonesia : Acta Pharm Indo Vol 10 No 1 (2022): Acta Pharmaciae Indonesia : Acta Pharm Indo
Publisher : Pharmacy Department, Faculty of Health Sciences, Jenderal Soedirman University, Purwokerto, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20884/1.api.2022.10.1.5776

Abstract

Background: COVID-19 is associated to an oxidant-antioxidant imbalance, which leads to inflammation and tissue damage. N-Acetylcysteine (NAC), in addition to being a mucolytic, has been shown to be an effective antioxidant in the therapy of COVID-19. Objective: The purpose of this study is to evaluate at the NAC usage profile in COVID-19 inpatients at Santa Elisabeth Hospital in Purwokerto. Methods: A descriptive observational design was used to perform the study. Retrospective data were obtained from medical records from July 2020 to July 2021. All patients who met the inclusion criteria were sampled using the total sampling technique. Results: NAC was commonly administered to COVID-19 inpatients who have a mild illness of the disease. The most common symptoms were cough and fever. Patients with mild and moderate severity were given NAC orally (600 mg 3 times a day) and intravenously (5 gram/day), respectively. The duration of NAC administration was in the range of 8-14 days. Conclusion: NAC was one of the therapies used at Santa Elisabeth Hospital Purwokerto for COVID-19 inpatients.
Potensi interaksi obat nutrasetikal pada epilepsi anak Nialiana Endah Endriastuti; Masita Wulandari Suryoputri; Dewi Latifatul Ilma; Tunggul Adi Purwonugroho
Acta Pharmaciae Indonesia : Acta Pharm Indo Vol 10 No 1 (2022): Acta Pharmaciae Indonesia : Acta Pharm Indo
Publisher : Pharmacy Department, Faculty of Health Sciences, Jenderal Soedirman University, Purwokerto, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20884/1.api.2022.10.1.4352

Abstract

Background: The trend of using nutraceuticals in Indonesia increases every year. This study aims to describe nutraceuticals consumed in pediatrics with epilepsy as additional antiepileptic therapy and analyze their potential drug interactions. Methods: This research was a cross-sectional study with total sampling method which was carried out in the period of June to July 2020. Inclusion criteria were children with epilepsy aged 0-17 years who were members of the Indonesian Epilepsy Community, had a doctor's diagnosis of epilepsy, received oral antiepileptic medication, and took nutraceutical products/food supplements. Data were analyzed descriptively based on data obtained through electronic data filling sheets and interviews. Results: There were 106 participants from the Indonesian Epilepsy Community in total, with 14 children (13.2 %) using nutraceutical supplements. They were male (n=8; 57.1%), 2-12 years old (n=10; 71.4%), and good nutritional status (n=10; 71.4%). Most nutraceuticals consumed were dietary supplements containing vitamins (n=10; 71.4%). Of the eight potential drug interactions identified, 25% (n=2) were significant interactions, and 75% (n=6) were minor interactions. The potential for major interactions occurred in administering nutraceutical products containing vitamin D with the antiepileptic drug phenytoin and phenobarbital. Conclusion: In this study, nutraceuticals and antiepileptic drugs had a little clinically meaningful interaction effect.
Co-Authors Dewi Latifatul Ilma Faradina Qorina Nadzif Heny Ekowati Nialiana Endah Endriastuti Tunggul Adi Purwonugroho